| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2020: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In the chemotherapy for elderly cancer patients, in which risk-benefit balance is generally small, quality of life (QOL) is an important outcome of treatment effectiveness. Based on the data from 3 large scale multi-institutional trials, we examined whether QOL was a predictor of important treatment outcomes after adjustment for performance status, age, gender, clinical stage, histology, and cognitive function, and clarified that preteratment QOL, measured using FACT-L scale, was an independent prognostic factor for overall survival. In addition, we investigated the “clinically meaningful” QOL change in the assessment of neurotoxicity, which is one of the important adverse events caused by cancer chemotherapy, and demonstrated that a 4-point deterioration in the FACT/GOG- Ntx score corresponded to the 1-grade worsening of physician-assessed CTCAE.
|
